Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- RLMD
- Price
- 0.68
- Stock movement down
- -0.00 (-0.41%)
- Company name
- Relmada Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 20.25M
- Ent value
- 26.86M
- Price/Sales
- -
- Price/Book
- 0.43
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -78.89%
- 3 year return
- -72.22%
- 5 year return
- -56.05%
- 10 year return
- -32.74%
Last updated: 2025-09-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
RLMD does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.43 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 33.19M |
| EPS (TTM) | -2.87 |
| FCF per share (TTM) | -1.76 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -91.64M |
| Net income (TTM) | -86.49M |
| EPS (TTM) | -2.87 |
| EPS (1y forward) | -0.99 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.48M |
| Net receivables | 0.00 |
| Total current assets | 55.70M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 55.72M |
| Accounts payable | 2.35M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 8.09M |
| Total liabilities | 8.10M |
| Shareholder's equity | 47.63M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -53.21M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -53.21M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -181.60% |
| Return on Assets | -155.21% |
| Return on Invested Capital | -181.60% |
| Cash Return on Invested Capital | -111.72% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.61 |
| Daily high | 0.64 |
| Daily low | 0.59 |
| Daily Volume | 69K |
| All-time high | 74.40 |
| 1y analyst estimate | 1.00 |
| Beta | 0.67 |
| EPS (TTM) | -2.87 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 6 Nov 2025 |
Downside potential
Loading...
Downside potential data
| RLMD | S&P500 | |
| Current price drop from All-time high | -99.18% | -1.46% |
| Highest price drop | -99.66% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -77.32% | -10.99% |
| Avg time to new high | 171 days | 12 days |
| Max time to new high | 2589 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
20.25M
Marketcap category
Small-cap
Description
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Employees
17
Website
Investor relations
-
SEC filings
CEO
Sergio Traversa
Country
USA
City
New York
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page